-
Journal of the American Academy of... Aug 2021
Topics: Alopecia; Fibrosis; Humans; Scalp
PubMed: 34033818
DOI: 10.1016/j.jaad.2021.05.015 -
Journal of the American Academy of... May 2023
Topics: Humans; Adolescent; Alopecia Areata; Retrospective Studies; Alopecia; Pyrazoles
PubMed: 36623557
DOI: 10.1016/j.jaad.2022.12.033 -
Journal of the American Academy of... Feb 2022
Topics: Alopecia; Alopecia Areata; Humans
PubMed: 34800602
DOI: 10.1016/j.jaad.2021.11.013 -
Facial Plastic Surgery Clinics of North... May 2020Androgenetic alopecia (AGA) is the most common hair loss disorder in men and women. The characteristic and reproducible balding pattern in AGA negatively affects... (Review)
Review
Androgenetic alopecia (AGA) is the most common hair loss disorder in men and women. The characteristic and reproducible balding pattern in AGA negatively affects self-image and the external perceptions of the balding patient. The phenotypical changes are driven by dihydrotestosterone (DHT) and its precursor testosterone. DHT induces follicle miniaturization and hair cycle changes until resulting hairs no longer extrude through the skin surface. AGA is inherited in a polygenetic pattern and is susceptible to epigenetic and environmental factors. Currently, minoxidil, finasteride, and photolaser therapy are the only Food and Drug Administration-approved medical treatments for AGA.
Topics: Alopecia; Dihydrotestosterone; Dutasteride; Finasteride; Hair Preparations; Humans; Low-Level Light Therapy; Minoxidil
PubMed: 32312501
DOI: 10.1016/j.fsc.2020.01.004 -
Journal of Cosmetic Dermatology Mar 2024Topical minoxidil is the recommended first-line pharmacologic treatment for male and female pattern hair loss. However, low-dose oral minoxidil has been used off-label... (Randomized Controlled Trial)
Randomized Controlled Trial
BACKGROUND
Topical minoxidil is the recommended first-line pharmacologic treatment for male and female pattern hair loss. However, low-dose oral minoxidil has been used off-label with good clinical efficacy and safety.
AIM
To compare the effectiveness and safety of topical minoxidil as a first-choice treatment of androgenetic alopecia versus 1 mg daily oral minoxidil.
METHOD
Sixty-five AGA patients were randomly allocated to receive either 5% topical solution or 1 mg/day oral minoxidil for 6 months. Treatment efficacy was evaluated by measuring hair diameter, photographic assessment, and patient self-assessment questionnaires. The safety of treatment was checked through history taking and physical examination.
RESULTS
Both topical and oral minoxidil groups showed significant improvement in hair diameter after 6 months of treatment (p < 0.001). However, there was no significant difference between the two groups. The photographic assessment demonstrated a significant improvement in hair density in the topical minoxidil group in all marked points located at 12 cm (p = 0.025), 16 cm (p = 0.034), and 24 cm (p = 0.014) distance from the glabella but not in the oral minoxidil group. Nevertheless, the difference between the two groups was not significant. In each group, over 60% of patients expressed satisfaction with their treatments, and no significant difference was detected between the two groups.
CONCLUSION
Although topical minoxidil has a better overall therapeutic effect than 1 mg oral minoxidil, the difference between the two groups was not significant. Therefore, 1 mg oral minoxidil may be as effective and safe as standard topical minoxidil in female and male pattern hair loss.
Topics: Humans; Female; Male; Minoxidil; Alopecia; Treatment Outcome; Hair; Photography
PubMed: 38031516
DOI: 10.1111/jocd.16086 -
Dermatologic Surgery : Official... Nov 2021
Topics: Alopecia; Humans; Male
PubMed: 34608090
DOI: 10.1097/DSS.0000000000003201 -
JAMA Dermatology Apr 2021
Topics: Alopecia; Dermatologists; Humans
PubMed: 33688909
DOI: 10.1001/jamadermatol.2020.5731 -
The Medical Clinics of North America Jul 2021Alopecia is a dermatologic condition in which sudden or gradual loss of hair occurs on 1 or more areas of the body, most commonly the scalp. Hair loss can be acute or... (Review)
Review
Alopecia is a dermatologic condition in which sudden or gradual loss of hair occurs on 1 or more areas of the body, most commonly the scalp. Hair loss can be acute or chronic in nature as a result of underlying inflammation, autoimmune processes, stressors, chemotherapy, or hairstyling practices. Alopecia can have substantial psychological consequences, having a negative impact on the quality of life in affected patients. The ability to both recognize and distinguish these condition holds great significance not only in providing adequate and timely treatment to improve outcomes but also meeting patient needs.
Topics: Adolescent; Adult; Alopecia; Child; Cicatrix; Female; Humans; Male; Middle Aged; Prevalence; Quality of Life; Severity of Illness Index; United States; Young Adult
PubMed: 34059240
DOI: 10.1016/j.mcna.2021.04.002 -
ACS Biomaterials Science & Engineering May 2023Pathological hair loss (also known as alopecia) and shortage of hair follicle (HF) donors have posed an urgent requirement for HF regeneration. With the revelation of... (Review)
Review
Pathological hair loss (also known as alopecia) and shortage of hair follicle (HF) donors have posed an urgent requirement for HF regeneration. With the revelation of mechanisms in tissue engineering, the proliferation of HFs in vitro has achieved more promising trust for the treatments of alopecia and other skin impairments. Theoretically, HF organoids have great potential to develop into native HFs and attachments such as sweat glands after transplantation. However, since the rich extracellular matrix (ECM) deficiency, the induction characteristics of skin-derived cells gradually fade away along with their trichogenic capacity after continuous cell passaging in vitro. Therefore, ECM-mimicking support is an essential prelude before HF transplantation is implemented. This review summarizes the status of providing various epidermal and dermal cells with a three-dimensional (3D) scaffold to support the cell homeostasis and better mimic in vivo environments for the sake of HF regeneration. HF-relevant cells including dermal papilla cells (DPCs), hair follicle stem cells (HFSCs), and mesenchymal stem cells (MSCs) are able to be induced to form HF organoids in the vitro culture system. The niche microenvironment simulated by different forms of biomaterial scaffold can offer the cells a network of ordered growth environment to alleviate inductivity loss and promote the expression of functional proteins. The scaffolds often play the role of ECM substrates and bring about epithelial-mesenchymal interaction (EMI) through coculture to ensure the functional preservation of HF cells during in vitro passage. Functional HF organoids can be formed either before or after transplantation into the dermis layer. Here, we review and emphasize the importance of 3D culture in HF regeneration in vitro. Finally, the latest progress in treatment trials and critical analysis of the properties and benefits of different emerging biomaterials for HF regeneration along with the main challenges and prospects of HF regenerative approaches are discussed.
Topics: Humans; Hair Follicle; Dermis; Regeneration; Alopecia; Tissue Engineering
PubMed: 37036820
DOI: 10.1021/acsbiomaterials.3c00028 -
Dermatologic Surgery : Official... Aug 2022Cosmetic procedures for antiaging carry inherent risks of adverse events. One that has not yet been well characterized is transitory or permanent alopecia. This is... (Review)
Review
BACKGROUND
Cosmetic procedures for antiaging carry inherent risks of adverse events. One that has not yet been well characterized is transitory or permanent alopecia. This is attributable to numerous mechanisms including pressure, ischemia, inflammation, and necrosis. Cases of postcosmetic procedure alopecia have been reported after mesotherapy as well as hyaluronic acid filler, deoxycholic acid, and botulinum toxin injections.
OBJECTIVE
This review serves to describe the currently known causes of postcosmetic procedure alopecia and the mechanisms by which alopecia is attained. Furthermore, this review highlights the risk of unregulated mesotherapy injections for cosmetic enhancement and to bring attention to the increasing number reports of alopecia after these procedures.
METHODS
A systematic review of the literature from 2000 to 2022 was conducted looking for keywords such as "alopecia," "cosmetic procedures," "mesotherapy," and "hyaluronic acid" in Google Scholar and PubMed.
RESULTS
Ten articles met the criteria set forth in the authors' literature review. Many of the procedures resulted in partial or complete resolution of alopecia.
CONCLUSION
Alopecia after cosmetic injection procedures is an underreported adverse effect. More research is needed to further characterize the risk of alopecia after mesotherapy and other injection procedures.
Topics: Alopecia; Cosmetic Techniques; Humans; Hyaluronic Acid; Mesotherapy
PubMed: 35642921
DOI: 10.1097/DSS.0000000000003498